United Therapeutics UTHR Other income, net (Note 6)
Other income, net (Note 6) at other companies
Other financials
Where this comes from
Reported directly by United Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's other income, net (note 6).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's other income, net (note 6)?
- United Therapeutics (UTHR) reported other income, net (note 6) of -$46.3M in Q1 2026.
- How has United Therapeutics's other income, net (note 6) changed year-over-year?
- United Therapeutics's other income, net (note 6) decreased by 976.7% year-over-year, from -$4.3M to -$46.3M.
- What is the long-term trend for United Therapeutics's other income, net (note 6)?
- Over 2 years (2022 to 2025), United Therapeutics's other income, net (note 6) has grown at a 10.3% compound annual growth rate (CAGR), from -$40.2M to $48.9M.
- What does other income, net (note 6) mean?
- This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.